Literature DB >> 12544295

Prognostic implications of p53 gene mutations in bladder tumors.

J G Lorenzo-Romero1, A S Salinas-Sánchez, J M Giménez-Bachs, F Sánchez-Sánchez, J Escribano-Martínez, M Segura-Martín, I R Hernandez-Millán, J A Virseda-Rodríguez.   

Abstract

PURPOSE: Alterations in the p53 gene related to neoplastic progression were studied in tumor tissue samples from patients with transitional cell carcinoma and correlated with classic staging parameters. On this basis, biological characterization of the tumor was performed to establish subgroups of patients at high risk and those with a more favorable prognosis.
MATERIALS AND METHODS: This observational, analytical and cross-sectional study included 115 patients divided into 4 homogeneous groups of 1-control, 2-primary superficial transitional cell carcinoma, 3-recurrent superficial transitional cell carcinoma, and 4-infiltrative transitional cell carcinoma. DNA was obtained from tumor tissue samples and polymerase chain reaction-single strand conformational polymorphism analysis was performed on exons 5 to 9 of the p53 gene. Samples showing mutations were submitted to automatic sequencing. Statistics included bivariate analysis and logistic regression.
RESULTS: Of the tumors the 63.8% were superficial and 37.2% were infiltrative transitional cell carcinoma. Of the infiltrative tumors 23.5% (8 of 34) resulted from recurrent transitional cell carcinoma. Mutations were found in samples from 46.8% of patients, all with bladder tumors. There was a trend toward increasing appearance of mutations as the size of the tumor, number of tumor implants, degree of dedifferentiation and stage of local infiltration increased. The presence of mutations in p53 was 2.5 times greater in infiltrative tumors than in low stage and 4.3 times greater in moderate to high grade than in low grade tumors. All mutations found were point mutations and 79.25% provoked severe alterations in protein structure.
CONCLUSIONS: Mutations in the p53 gene are mainly point mutations that aggregate in hot spots, and provoke genetic instability and substantial changes that alter p53 function, implying a trend to tumor progression and dissemination (with a greater proportion of mutations in high stage high grade tumors). Since a large percentage of bladder tumors are under staged, analysis of p53 gene mutations could be useful as a factor for prognosis and therapeutic decisions.

Entities:  

Mesh:

Year:  2003        PMID: 12544295     DOI: 10.1097/01.ju.0000046224.57330.70

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

Review 1.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

Review 2.  Recent advances in treatment of advanced urothelial carcinoma.

Authors:  Jenny J Kim
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

3.  Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer.

Authors:  Farha A El-Chennawi; Fatma A Auf; Shereen S Metwally; Youssef M Mosaad; Atallah A Shaaban; Mahmoud Abdo El-Baz; Ziyad E Tawhid; Zakaria F Lotfy
Journal:  World J Gastrointest Oncol       Date:  2009-10-15

4.  Current therapeutic strategies for invasive and metastatic bladder cancer.

Authors:  Prakash Vishnu; Jacob Mathew; Winston W Tan
Journal:  Onco Targets Ther       Date:  2011-07-11       Impact factor: 4.147

5.  A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.

Authors:  Xiangkun Wu; Daojun Lv; Chao Cai; Zhijian Zhao; Ming Wang; Wenzhe Chen; Yongda Liu
Journal:  Front Immunol       Date:  2020-12-17       Impact factor: 7.561

6.  The Relationship of Pyroptosis-Related Genes, Patient Outcomes, and Tumor-Infiltrating Cells in Bladder Urothelial Carcinoma (BLCA).

Authors:  Ruiyan Xie; Ming Xie; Litong Zhu; Joanne W Y Chiu; Wayne Lam; Desmond Y H Yap
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

7.  Gene network screening of bladder cancer via modular analysis.

Authors:  Xiaodong Li; Ye Wu; Ye Yuan
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.